Actively Recruiting
ExtraCorporeal Membrane Oxygenation in the Therapy for REfractory Septic Shock With Cardiac Function Under Estimated
Led by Second Affiliated Hospital of Guangzhou Medical University · Updated on 2024-02-21
64
Participants Needed
1
Research Sites
160 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The ECMO-RESCUE study is a prospective, multicenter, non-randomized, cohort study. In this study, we aimed to assessed whether VA-ECMO treatment can improve the 30-day survival rate of patients with sepsis-induced refractory cardiogenic shock.
CONDITIONS
Official Title
ExtraCorporeal Membrane Oxygenation in the Therapy for REfractory Septic Shock With Cardiac Function Under Estimated
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years
- Admitted to ICU with septic shock based on sepsis-3.0 criteria
- After fluid resuscitation and high-dose vasoactive drugs (vasoactive inotropic score >120), have at least one of: sustained low blood pressure (MAP < 65 mmHg); persistent high lactate levels (>5 mmol/L) despite steady drug support; or low mixed venous oxygen saturation (<55%) with steady drug support
- Above conditions last more than 5 hours
- Rapidly worsening heart function shown by one or more: left ventricular ejection fraction below 35%; cardiac index under 2 L/min/m2 for over 3 hours; or new refractory arrhythmia
- Provided informed consent by patient or decision maker
You will not qualify if you...
- Cardiac dysfunction caused by other conditions like acute myocardial infarction, chronic heart failure, congenital heart disease, myocardial effusion, moderate to severe aortic regurgitation, or severe aortic coarctation
- Suspected pulmonary embolism, tension pneumothorax, or cardiac tamponade causing shock
- Cardiac arrest longer than 30 minutes before ECMO or coma after CPR
- Irreversible condition or meeting inclusion criteria for more than 12 hours
- Active bleeding or contraindications to anticoagulants
- Peripheral artery disease preventing insertion of outflow cannula into femoral artery
- Irreversible neurological damage
- Severe underlying condition with life expectancy less than 1 year
- Pregnancy or acquired immune deficiency syndrome (AIDS)
- Participation in another interventional clinical trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chen Weiyan
Guangzhou, Guangdong, China, 510260
Actively Recruiting
Research Team
W
Wei-yan Chen
CONTACT
D
De-liang Wen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here